Zydus Lifesciences

瑞迪博士生命科学公司

on Wednesday said it has launched a

周三表示已推出一项

biosimilar

生物仿制药

for the treatment of osteoporosis and the prevention of skeletal complications in

用于治疗骨质疏松症和预防骨骼并发症

cancer patients

癌症患者

.

。

The company has launched Zyrifa, a

公司已经推出了 Zyrifa，

Denosumab

地诺单抗

biosimilar.

生物仿制药。

Denosumab is a monoclonal antibody with several indications related to

地诺单抗是一种单克隆抗体，具有多种相关适应症

bone health

骨骼健康

, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients.

，主要用于治疗骨质疏松症和预防癌症患者的骨骼并发症。

This will provide access and treat patients with

这将提供访问并治疗患者的能力

bone metastases

骨转移

due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours, the Ahmedabad-based drug firm said in a regulatory filing.

由于乳腺癌、前列腺癌、肺癌、骨髓瘤、肾癌、甲状腺癌、头颈癌和其他实体肿瘤，总部位于艾哈迈达巴德的制药公司在一份监管文件中表示。

Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer.

转移是指癌细胞扩散到骨骼和身体其他器官，表明癌症已进入晚期。

Live Events

现场活动

The company said it has priced 'Zyrifa' at MRP of Rs 12,495.

该公司表示，“Zyrifa”的定价为12495卢比。

Sharvil P Patel, Managing Director, Zydus Lifesciences Ltd said that with Denosumab 120 mg SC, the company aims to bring access, affordability of medication in cancer patients needing critical care.

Zydus Lifesciences Ltd董事总经理Sharvil P Patel表示，通过Denosumab 120 mg SC，公司旨在为需要重症监护的癌症患者提供药物的可及性和可负担性。

'This will help patients to retain mobility, and support them in their fight against cancer,' he added.

“这将帮助患者保持活动能力，并支持他们对抗癌症，”他补充道。

Population scale analyses and registry studies consistently show high bone involvement rates in advanced disease; in advanced breast or prostate cancer, bone involvement affects 50 -70 per cent of patients, whereas 15- 40 per cent of lung, kidney, thyroid, and melanoma cases also develop skeletal metastases over time..

大规模人群分析和注册研究一致表明，在晚期疾病中骨骼受累率很高；在晚期乳腺癌或前列腺癌中，50%-70%的患者出现骨骼受累，而15%-40%的肺癌、肾癌、甲状腺癌和黑色素瘤病例也会随着时间的推移发展为骨转移。

Zydus Lifesciences said it has been launching a wide range of biosimilars to treat various cancers ranging from breast cancer to prostate cancer, various other solid tumours and blood cancer.

Zydus Lifesciences 表示，它已经推出了一系列广泛的生物类似药，用于治疗从乳腺癌到前列腺癌、各种其他实体瘤和血癌等多种癌症。

The company has also partnered with diagnostic companies, it added.

该公司还与诊断公司合作。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)